Actelion

Johnson & Johnson reported slightly better-than-expected quarterly profit on Tuesday and pushed its full-year forecast higher, as demand for its c(...)

Pharma giant Johnson & Johnson reported a higher-than-expected quarterly profit and raised its full-year forecast, driven by strong demand for its(...)

Johnson & Johnson raised its full-year profit forecast and reported better-than-expected quarterly earnings on Tuesday, helped by strong demand f(...)

European shares held around one-year highs on Thursday, supported by mergers and acquisitions-related optimism, with Johnson & Johnson’s $30 billi(...)

Johnson and Johnson (JandJ) has agreed to buy Actelion for $30 billion (€28.1bn), clinching one of its largest ever deals to become a leader in medici(...)

Johnson & Johnson is negotiating a deal to acquire Swiss biotechnology company Actelion Ltd that would separate Actelion’s commercialised portfoli(...)

European stocks inched lower amid thin trading, with investors signalling reluctance to extend a rally as the last full trading week of 2016 unfolded.(...)

In a surprise twist to one of 2016’s biggest potential health deals, Actelion and US drug giant Johnson and Johnson are back at the negotiating table (...)

Swiss biotech group Actelion’s shares rose by more than 3 per cent on Wednesday following a report that talks with Sanofi are making progress, increas(...)

European stocks climbed to an 11-month high on merger and acquisition speculation on Friday, while the dollar’s rally paused as investors adjusted the(...)